Y-mAbs Therapeutics (NASDAQ:YMAB) Earns “Outperform” Rating from Wedbush
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research note issued on Friday,RTT News reports. They currently have a $23.00 price objective on the stock. Wedbush’s price target indicates a potential upside of 233.82% from the stock’s previous close. A number of other equities […]
More Stories
Why Offices Sound Worse Than Ever, And the Engineering Fix Hiding in Plain Sight
Open-plan offices were meant to feel modern, bright, and collaborative. In reality, many feel like a mix of café, hallway,...
Ice Age 6: Boiling Point- Release Date, Voice Artist, and Synopsis
Hello, Ice Age fans! Your favourite animated animal movie is returning to the US theaters. Ice Age 6, or Ice...
I Will Find You: Sam Worthington’s Upcoming Series
Netflix is coming up with an all-new miniseries featuring the famous Sam Worthington as Jake Sully from the 2009 film...
Big Mistakes Season 2: Release Date, Cast, and Synopsis
Netflix’s hit comedy-thriller series, Big Mistakes, got an official renewal. The dark comedy series is bringing back the humor of...
Top 11 E-Commerce Companies in the USA for Your Convenience
There are a huge number of e-commerce companies in the USA. These companies are growing exponentially with the increasing demand....
Strip Law Season 2 Renewed? Check out the Renewal Status
Netflix is cancelling one series after another, and Strip Law, the American adult animated sitcom, is among them. Netflix has...